Back to NVSView Full Landscape
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Upcoming Catalysts
What are catalysts?Competitive Landscape
6 competitors in Carcinoma, Non-Small-Cell Lung
PBYIHKI-272
Phase 2JNJJNJ-90301900
Phase 2LLYIMC-1121B (ramucirumab)
Phase 2CASIrecombinant human Angiostatin protein
Phase 2GTHXG1T38
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA6/20/2022
Tabrecta
Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts